利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

86 条记录 (耗时 0.017 秒)

    PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
    1.
    发明申请
    PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 失效

    公开(公告)号：US20080039388A1

    公开(公告)日：2008-02-14

    申请号：US11678535

    申请日：2007-02-23

    申请人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

    发明人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

    IPC分类号： A61K38/16 ,  A61P17/00 ,  A61P9/00 ,  C07K14/00

    CPC分类号： C07K14/75 ,  A61K38/00 ,  Y02A50/385

    摘要： Peptides and peptide derivatives of the following general Formula I: H2H-GHRPX1X2X3X4X5X6X7X8X9X10-(I) X11PX12PPPX13X14X15X16GYR-X17, wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen or (C1-C10)-alkyl, as well as the physiologically acceptable salts thereof.

    Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
    2.
    发明授权
    Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms 失效
    用于治疗出血性休克及其连续症状的药物组合物

    公开(公告)号：US07897574B2

    公开(公告)日：2011-03-01

    申请号：US12158670

    申请日：2006-11-10

    申请人： Peter Petzelbauer ,  Rainer Henning

    发明人： Peter Petzelbauer ,  Rainer Henning

    IPC分类号： A61K38/36

    CPC分类号： A61K38/16 ,  Y02A50/411

    摘要： The invention is concerned with the use of a peptide comprising the N-terminal sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (SEQ ID NO: 1) or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the Bβ-chain (i.e. Bβ15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.

    摘要翻译： 本发明涉及使用包含N-末端序列Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro- （SEQ ID NO：1）或具有与诱导型VE-钙粘蛋白结合基序匹配的生物学特性的所述肽的任何等位基因变体或衍生物（Pro-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg 在人类纤维蛋白的B＆bgr-chain（即B＆Bgr; 15-42）上制备用于治疗休克的药物制剂，更具体地说是出血性休克。

    (En) Pharmaceutical Composition for Treating Haemorrhagic Shock and its Consecutive Symptoms
    4.
    发明申请
    (En) Pharmaceutical Composition for Treating Haemorrhagic Shock and its Consecutive Symptoms 失效
    （En）用于治疗出血性休克及其连续症状的药物组合物

    公开(公告)号：US20090005310A1

    公开(公告)日：2009-01-01

    申请号：US12158670

    申请日：2006-11-10

    申请人： Peter Petzelbauer ,  Rainer Henning

    发明人： Peter Petzelbauer ,  Rainer Henning

    IPC分类号： A61K38/17 ,  A61P7/04 ,  C12Q1/02

    CPC分类号： A61K38/16 ,  Y02A50/411

    摘要： The invention is concerned with the use of a peptide comprising the N-terminal sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala- Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly- Gly-Gly-Tyr-Arg or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the Bβ-chain (i.e. Bβ15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.

    摘要翻译： 本发明涉及使用包含N-末端序列的肽

    Pro-Ser-Leu-Arg-Pro-Ala-Pro -Pro-Pro-Ile-Ser-Gly - Gly-Gly-Tyr-Arg 或具有与Bbeta链上的诱导型VE-钙粘蛋白结合基序匹配的生物学特性的所述肽的任何等位基因变体或衍生物（即Bbeta15 -42），用于制备用于治疗休克的药物制剂，更具体地说是出血性休克。

      PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
      7.
      发明申请
      PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 审中-公开
      肽和肽衍生物作为含有其的药物组合物

      公开(公告)号：US20100279924A1

      公开(公告)日：2010-11-04

      申请号：US12820804

      申请日：2010-06-22

      申请人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      发明人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P31/12 ,  A61P29/00 ,  A61P7/00 ,  A61P11/00 ,  A61P43/00

      CPC分类号： C07K14/75 ,  A61K38/00 ,  Y02A50/385

      摘要： Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

      摘要翻译： 治疗组合物可以包括衍生自Bβ（15-42） - 纤维蛋白片段的链的修饰肽，并且其中序列的一个或几个氨基酸已被遗传编码的或未经遗传编码的氨基酸或肽模拟物取代。 它们可以作为游离肽或C末端衍生物存在和/或与聚乙二醇（PEG） - 聚合物连接，并具有抗炎和/或内皮稳定作用。 酯或酰胺可以例如被考虑为C末端衍生物。 还描述了肽及其衍生物的制备方法。

      PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
      8.
      发明申请
      PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 审中-公开
      肽和肽衍生物作为含有其的药物组合物

      公开(公告)号：US20110098442A1

      公开(公告)日：2011-04-28

      申请号：US12280543

      申请日：2007-02-23

      申请人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      发明人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      IPC分类号： C07K14/00

      CPC分类号： C07K14/75 ,  A61K38/00 ,  Y02A50/385

      摘要： Peptides and peptide derivatives of the following general Formula (I): H2N-GHRPX1X2X3X4X5X6X7X8X9X10X11PX12PPPX13X14X15X16GYR—X17 (I), wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen or (C1-C10)-alkyl, as well as the physiologically acceptable salts thereof.

      摘要翻译： 下列通式（I）的肽和肽衍生物：H2N-GHRPX1X2X3X4X5X6X7X8X9X10X11PX12PPPX13X14X15X16GYR-X17（I），其中：X1-X16表示20个遗传编码氨基酸之一，X17表示OR1，其中R1 =氢或（C1-C10 - 烷基）或NR 2 R 3，R 2和R 3相同或不同，表示氢，（C 1 -C 10） - 烷基或残基-PEG 5-60K，其中PEG残基通过间隔基与N原子相连，或 残基NH-YZ-PEG5-60K，其中Y表示S，C，K或R组中的化学键或遗传编码的氨基酸，Z表示间隔基，通过其可以使用聚乙二醇（PEG） 可以连接残基，以及其生理上可接受的盐，或其中：X15或X16表示C或K基团的氨基酸，其通过侧面的杂原子与残基Z-PEG5-60K连接 链，其中X17表示OR1，其中R1 =氢或（C1-C10-烷基）或NR2R3，R2和R3相同或不同，表示氢 基或（C 1 -C 10） - 烷基，以及其生理上可接受的盐。

      Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
      9.
      发明授权
      Peptides and peptide derivatives as well as pharmaceutical compositions containing the same 失效
      肽和肽衍生物以及含有它们的药物组合物

      公开(公告)号：US07799758B2

      公开(公告)日：2010-09-21

      申请号：US11678535

      申请日：2007-02-23

      申请人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      发明人： Peter Petzelbauer ,  Rainer Henning ,  Sonja Reingruber

      IPC分类号： A61K38/16 ,  C07K14/00

      CPC分类号： C07K14/75 ,  A61K38/00 ,  Y02A50/385

      摘要： Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

      摘要翻译： 治疗组合物可以包括衍生自Bβ（15-42） - 纤维蛋白片段的链的修饰肽，并且其中序列的一个或几个氨基酸已被遗传编码的或未经遗传编码的氨基酸或肽模拟物取代。 它们可以作为游离肽或C末端衍生物存在和/或与聚乙二醇（PEG） - 聚合物连接，并具有抗炎和/或内皮稳定作用。 酯或酰胺可以例如被考虑为C末端衍生物。 还描述了肽及其衍生物的制备方法。